Companies HOOKIPA Pharma
HOOKIPA Pharma (HOOK): executive pay, fiscal 2023
Free brief. Every figure links to the company’s own filing.
HOOKIPA Pharma no longer files a proxy statement; its last pay data is FY2023.
CEO pay, last three years
- $1,250,408FY2022
- $1,130,427FY2023
CEO total pay was $1,130,427 in fiscal 2023, down from $1,250,408 in fiscal 2022.
FY2023: salary $567,451 · bonus $0 · stock awards $0 · option awards $282,088
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Joern Aldag | $567,451 | $0 | $0 | $282,088 | $280,888 | $0 | $0 | $1,130,427 |
| Chief Executive Officer | ||||||||
| Christine Baker | 477,000 | 0 | 0 | 151,479 | 171,720 | 0 | 13,200 | 813,399 |
| Former Chief Operating Officer | ||||||||
| Reinhard Kandera | 436,001 | 0 | 0 | 117,976 | 156,960 | 0 | 14,538 | 725,475 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Joern Aldag | $1,130,427 | $1,250,408 | — | ↓ −119,981 |
| Christine Baker | 813,399 | 873,624 | — | ↓ −60,225 |
| Reinhard Kandera | 725,475 | 715,161 | — | ↑ +10,314 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation philosophy is designed to align the interests of named executive officers with those of stockholders, motivate executives to make important contributions to performance, and attract and retain highly-qualified executives. The program utilizes base salary, annual cash bonuses based on corporate and individual goals, and long-term equity incentives (primarily stock options) to provide a means to build real ownership in the Company and contribute to executive retention.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Radford |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2023
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Joern Aldag | OPTION | — | — | — | 513,600 | — | $282,088 |
| Christine Baker | OPTION | — | — | — | 275,800 | — | 151,479 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Joern Aldag | $0 | $0 | $282,088 | 0.0% |
| Christine Baker | 0 | 0 | 151,479 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2023
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Christine Baker | Option | 3,781 | 8.03 | — |
| Reinhard Kandera | Option | 4,837 | 8.03 | — |
| Joern Aldag | Option | 12,500 | 8.03 | — |
| Christine Baker | Option | 15,609 | 12 | — |
| Reinhard Kandera | Option | 21,656 | 12 | — |
| Reinhard Kandera | Option | 52,284 | 1.66 | — |
| Christine Baker | Option | 56,250 | 1.66 | — |
| Joern Aldag | Option | 64,875 | 12 | — |
| Joern Aldag | Option | 154,828 | 1.66 | — |
| Reinhard Kandera | Option | 214,800 | 1 | — |
| Christine Baker | Option | 275,800 | 1 | — |
| Joern Aldag | Option | 513,600 | 1 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Malte PetersNot independent · Science and Technology | $191,427 | — | $40,879 | — | — | $232,306 |
| Jan van de WinkelIndependent · Board Chair · Compensation (Chair) · Nominating and Corporate Governance (Chair) | 87,500 | — | 40,480 | — | — | 127,980 |
| Terry CoelhoIndependent · Audit (Chair) · Compensation | 45,000 | — | 40,879 | — | — | 85,879 |
| David R. KaufmanIndependent · Audit · Science and Technology | 51,500 | — | 20,240 | — | — | 71,740 |
| Timothy ReillyIndependent · Nominating and Corporate Governance · Science and Technology (Chair) | 51,500 | — | 20,240 | — | — | 71,740 |
| Julie O’NeillIndependent · Audit | 47,500 | — | 20,240 | — | — | 67,740 |
| Michael A. KellyIndependent · Compensation · Departed during FY | 15,000 | — | 0 | — | — | 15,000 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 7,500 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $489,427 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $489,427 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names HOOKIPA Pharma as a peer
Companies that benchmark against HOOK
3 companies name HOOK as a compensation peer
- ASSEMBLY BIOSCIENCES, INC.ASMBFY2025
- KYNTRA BIO, INC.FGENFY2025
- Shattuck Labs, Inc.STTKFY2025
Each company listed discloses HOOK in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named HOOK in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | HOOKIPA Pharma | 2023 | Joern Aldag | $567,451 | $0 | $282,088 | $280,888 | $1,130,427 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (16 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Joern Aldag. DEF 14A, filed 2024-04-26. Section “Executive Compensation”. As printed: 1,130,427. View filing ↗
- Section 01, Christine Baker. DEF 14A, filed 2024-04-26. Section “Executive Compensation”. As printed: 813,399. View filing ↗
- Section 01, Reinhard Kandera. DEF 14A, filed 2024-04-26. Section “Executive Compensation”. As printed: 725,475. View filing ↗
- Section 03, Joern Aldag OPTION. DEF 14A, filed 2024-04-26. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Christine Baker OPTION. DEF 14A, filed 2024-04-26. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, Malte Peters. DEF 14A, filed 2024-04-26. Section “Director Compensation”. As printed: 232,306. View filing ↗
- Section 08, Jan van de Winkel. DEF 14A, filed 2024-04-26. Section “Director Compensation”. As printed: 127,980. View filing ↗
- Section 08, Terry Coelho. DEF 14A, filed 2024-04-26. Section “Director Compensation”. As printed: 85,879. View filing ↗
- Section 08, David R. Kaufman. DEF 14A, filed 2024-04-26. Section “Director Compensation”. As printed: 71,740. View filing ↗
- Section 08, Timothy Reilly. DEF 14A, filed 2024-04-26. Section “Director Compensation”. As printed: 71,740. View filing ↗
- Section 08, Julie O’Neill. DEF 14A, filed 2024-04-26. Section “Director Compensation”. As printed: 67,740. View filing ↗
- Section 08, Michael A. Kelly. DEF 14A, filed 2024-04-26. Section “Director Compensation”. As printed: 15,000. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 489,427 + equity 0 + all other 0 = 489,427, summed across the director compensation table rows.
- HOOKIPA Pharma (subject), Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in HOOKIPA Pharma's own proxy. As printed: 1,130,427. View filing ↗